Epclusa and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Epclusa (sofosbuvir; velpatasvir), especially for people who are male, 60+ old, also take Zofran, and have Hepatitis c.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Epclusa. It is created by eHealthMe based on reports of 12,085 people who have side effects when taking Epclusa from the FDA, and is updated regularly.

What is Epclusa?

Epclusa has active ingredients of sofosbuvir; velpatasvir. eHealthMe is studying from 12,120 Epclusa users. Check the latest studies of Epclusa.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,327 drugs and 3,592 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

On Jul, 20, 2026

12,085 people reported to have side effects when taking Epclusa.
Among them, 13 people (0.11%) have Agranulocytosis.

Among these 13 people:

What is the gender of people who have Agranulocytosis when taking Epclusa? *

female: 30.77 %
male: 69.23 %

What is the age of people who have Agranulocytosis when taking Epclusa? *

What are other drugs people take besides Epclusa? *

What are other side effects people have besides Agranulocytosis? *

Thrombocytopenia (decrease of platelets in blood): 2 people, 15.38%
Subarachnoid Haemorrhage (blood leaks into the space between two membranes that surround the brain): 1 person, 7.69%
Sepsis (a severe blood infection that can lead to organ failure and death): 1 person, 7.69%
Peripheral Sensory Neuropathy (damage to one or more of your peripheral nerves): 1 person, 7.69%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 1 person, 7.69%
Myocarditis (inflammation of heart muscle myocardium): 1 person, 7.69%
Leukopenia (less number of white blood cells in blood): 1 person, 7.69%
Laboratory Test Abnormal: 1 person, 7.69%
Infection: 1 person, 7.69%
Febrile Neutropenia (fever with reduced white blood cells): 1 person, 7.69%

What are the existing conditions these people have? *

Hepatitis C: 8 people, 61.54%
Lymphoma (cancer that begins in immune system cells): 2 people, 15.38%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 7.69%
Pain: 1 person, 7.69%
Nausea (feeling of having an urge to vomit): 1 person, 7.69%
Multiple Myeloma (cancer of the plasma cells): 1 person, 7.69%
Itching: 1 person, 7.69%
Insomnia (sleeplessness): 1 person, 7.69%
Fungal Infection: 1 person, 7.69%
Enlarged Prostate: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Epclusa and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Epclusa:

Epclusa (12,120 reports)

Agranulocytosis treatments and more:

Agranulocytosis (213,267 reports)

Browse all side effects of Epclusa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Agranulocytosis (2,327 drugs)

Browse all the conditions that are associated with Agranulocytosis:

Agranulocytosis (3,592 conditions)

Related publications that referenced our studies

Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on sofosbuvir; velpatasvir (the active ingredients of Epclusa) and Epclusa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.